Analytica Limited Overview
Analytica Limited was a Queensland micro-cap medical-device developer. For more than a decade it tried to commercialise the PeriCoach System, a connected pelvic-floor muscle trainer for women with stress urinary incontinence. PeriCoach combined an intravaginal sensor device, a smartphone app and a clinician web portal. The underlying exercise data was pooled in a cloud database the company described as the world's largest of its kind. The company also held a legacy infusion franchise: the AutoStart burette, later grouped with AutoFlush as the Enhanced Infusion System. PeriCoach obtained TGA, CE-mark and US FDA clearances, including US over-the-counter clearance in 2016. Despite this, revenue never scaled beyond a few hundred thousand dollars a year. By June 2022 the company had accumulated losses of about A$107.6 million. Its 2021 pivot to sovereign manufacturing in Maryborough and its China joint venture did not produce sustainable revenue. The company entered administration in June 2023 and was removed from the ASX in August 2023.
What the company did. In its own corporate description, Analytica designed, developed and supplied Class I and Class II medical devices. Its stated aim was to build shareholder value by commercially developing viable, profitable devices. Third-party profiles (MarketBeat, Pearler) describe it as supplying medical devices in Australia, China and the Middle East. Those profiles name the PeriCoach System as the lead product and the AutoStart Burette Infusion System as the second product line.
Business model. Analytica was a product-led medical-technology company. It generated revenue mainly from hardware sales of the PeriCoach device. Sales went through four channels: direct-to-consumer, clinician-referred sales, wholesale distributors (for example Current Technology, Inc. in the US from 2015), and from 2021 regional joint-venture and distribution partners in China and the Middle East. The app and web portal were bundled with the device. Accessible disclosures show no separately monetised subscription or SaaS revenue line.
Value-chain position. Analytica was a design owner and regulatory sponsor. It outsourced manufacturing, first to a Sydney contract manufacturer from about 2014 and to offshore providers during the R&D and regulatory phases. It decided in 2021 to bring manufacturing in-house in Maryborough, citing better control of the supply chain and regulatory compliance.
Customer types and end-markets.
Independent characterisation. Analytica is a textbook example of a single-product ASX micro-cap medtech that won regulatory approval but never achieved commercial adoption. It obtained approvals in all three major Western regulatory systems (TGA, CE, FDA 510(k) and OTC) and built a defensible patent estate. However, it never found a partner with distribution scale. The company had said publicly in 2016 that it was looking for a major multinational partner, and no such deal was ever announced. Repeated reliance on loans from the chairman, small placements and government grants left the company structurally undercapitalised. This is consistent with management's own admission, reported by Biotech Daily in 2017, that limited capital had been a long-running difficulty.
Strategy
Stated strategy themes.
-
Prove the device, then partner (2015–2018). The 2015 annual report set two goals: prove PeriCoach clinically and commercially, then secure a multinational partner. The company built clinical evidence (post-approval trial, case studies, US early-adopter sites) and regulatory breadth (FDA OTC clearance) to reduce a partner's time to market.
-
Data as a moat. The company promoted the PeriVault exercise database as a basis for next-generation products.
-
Geographic expansion through partners (2021). It formed the China JV covering manufacturing, CFDA/NMPA Class II registration, and channels through hospitals, postpartum centres, pharmacy chains and online platforms. It also expanded Middle East distribution across ten nations.
-
Sovereign/regional manufacturing (2021–2022). It planned to bring production in-house at Maryborough, citing supply-chain control, regulatory compliance, responsiveness to distributors, and the ability to restart direct-to-consumer sales and pursue health-system and insurer deals.
Initiatives in the final 24 months as a listed company (Aug 2021 – Aug 2023).
Medium-term financial targets / guidance. None published.
ESG / sustainability commitments. None published.
Products & Services
PeriCoach System (pelvic health)
| Attribute | Detail |
|---|---|
| Description | Connected pelvic-floor muscle trainer with biofeedback. It has three parts: (1) an intravaginal sensor device that measures pelvic-floor muscle activity; (2) a smartphone app that guides Kegel exercises with real-time feedback; (3) a cloud web portal through which clinicians monitor patient progress. |
| Data asset | "PeriVault", which the company described as the world's largest pelvic-floor muscle exercise database |
| Indications | Stress urinary incontinence (primary). CE mark extended to pelvic organ prolapse. Postpartum rehabilitation and preventive senior-care positioning in China. |
| Target customers | Women with SUI (company claim: about 1 in 3 women have pelvic-floor problems), women's health physiotherapists, urogynaecologists, postpartum care centres, pharmacy chains |
| Regulatory status | TGA (Australia); CE mark (EU); US FDA clearance (March 2015) and OTC clearance (2016); planned registration as a Class II device with China's NMPA (formerly CFDA) through the JV (outcome not disclosed) |
| Versions | V1 commercial in November 2014; V2 (date not disclosed); V3 available from 1 May 2017 |
| IP | Patents in Australia, the US (including motion-sensor claims), China (2016), Europe and India |
| Pricing | Not publicly disclosed in accessible sources |
| Current status | Business sold to Stratos Medtech (2023). Stratos briefly held a Class I "Perineometer" ARTG entry (January–April 2024). |
Enhanced Infusion System (EIS): AutoStart and AutoFlush
| Attribute | Detail |
|---|---|
| Description | Technologies for intravenous infusion that monitor and automatically refill burettes. The project names were AutoStart and AutoFlush. |
| Target customers | Hospitals, especially paediatric and critical-care infusion settings where burettes are used |
| IP | AutoStart burette patent granted (reported in the June 2016 quarter) |
| Markets | Middle East expansion announced 31 March 2021 through Analytica Export ME Pty Ltd |
| Pricing / sales volumes | — |
Ancillary / adjacent offerings
| Offering | Detail |
|---|---|
| Maryborough call centre and data centre | Part of the 2021 facility plan, to support PeriCoach training, administration and data |
| Clinical evidence programme | Post-approval clinical trial, published case studies, and early-adopter US clinic sites (2015–16) |
| SportsMed integration (2014 MoU) | Planned access to women's sport and women-only gym markets. Non-binding; no conversion disclosed. |
Financial Narrative
Disclosure limitation. Analytica's last complete reported financial year is FY2022 (to 30 June 2022). No FY2023 annual report was published before administration. That document gives FY2022 revenue, FY2021 and FY2022 net losses, accumulated losses and net tangible assets (NTA) per share. All other cells are blank by design.
Income statement (AUD)
Sources: FY2022 Appendix 4E (revenue, net losses, nil dividends). Market Index records no dividend history for ALT.
Margins and growth
The FY2022 net margin is calculated as -2,238,553 / 285,726. A 5-year revenue CAGR cannot be computed because FY2017–FY2021 revenue is not available from verifiable sources.
Interim datapoints (AUD)
Sources: Biotech Daily, 2 June 2017 (H1 FY2017); Stockhead and Kalkine (H1 FY2021: revenue up 7% to about A$81k, net loss about A$0.45M). The A$1.99M H1 FY2017 "revenue" very probably includes R&D Tax Incentive income rather than product sales, since quarterly customer receipts at the time were tens of thousands of dollars. Treat it with caution.
Balance sheet (AUD)
Source: FY2022 Appendix 4E, items 8 and 9. Accumulated losses also reflect transfers from the option reserve of A$810,569 in FY2022 and A$41,619 in FY2021.
Key solvency observation. NTA per share was negative in both FY2021 and FY2022. With roughly 4.6 billion shares on issue (the count implied by MarketBeat's A$4.61M market capitalisation at A$0.001), an NTA of -A$0.0005 per share implies a net tangible liability position of roughly A$2.3M at 30 June 2022. This is an analyst derivation. The DOCA disclosure that about A$3.1M was owed to entities associated with chairman Dr Michael Monsour confirms that related-party debt was the principal funding source by 2023. Eulerpool reports latest equity of -A$146,700, but that figure could not be reconciled with primary filings and is not relied on.
Cash flow and ratios
Historical burn reference: quarterly cash outflows were about A$888,000 in the March 2017 quarter, with an estimated quarterly burn of A$955,000 (Biotech Daily 2017). Cash was A$1.234M at 31 March 2017, excluding A$1.02M of placement proceeds received afterwards.
Ratios. ROE, ROA and ROIC are not meaningful because the company was loss-making with negative tangible equity. Current ratio, debt/equity, net debt/EBITDA, asset turnover and cash conversion cycle are not publicly disclosed in accessible sources. Interest coverage is negative.
Commentary
Analytica's financial history is one of persistent losses against negligible commercial revenue. Accumulated losses passed A$107 million by June 2022. That is extraordinary relative to the company's revenue base, and it reflects decades of development spending, including the pre-PeriCoach burette era. The FY2022 results contain three inflections. First, revenue fell 64% to A$285,726. That reversed whatever gains the 2021 China and Middle East announcements had produced, which suggests early JV and distributor stocking orders did not repeat. Second, the net loss rose 48% to A$2.24M as Maryborough manufacturing preparation and corporate costs increased. Third, tangible net worth deteriorated further. By 2023 the company relied on director loans, and voluntary administration followed within about ten months of the FY2022 report.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Ownership | Function (inferred from name and disclosures) |
|---|---|---|
Analytica Limited | Parent; ASX-listed until Aug 2023 | Holding company, IP owner, regulatory sponsor |
PeriCoach Pty Ltd | 100% | PeriCoach product entity. Its shares were sold to Stratos under the 2023 DOCA. |
Analytica Operations Pty Ltd | 100% | Operating and manufacturing entity (Maryborough strategy) |
Analytica Export ME Pty Ltd | 100% | Middle East export vehicle for the infusion system and PeriCoach distribution |
Revenue by Segment (AUD)
| Segment | FY2021 | FY2022 |
|---|---|---|
Medical devices, consolidated revenue (AUD) | — | 285,726 |
Medical devices, net loss after tax (AUD) | -1,507,406 | -2,238,553 |
Income Statement (AUD)
| Metric | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Revenue from ordinary activities (AUD) | — | — | — | — | 285,726 |
Net loss attributable to members (AUD) | — | — | — | -1,507,406 | -2,238,553 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 |
|---|---|
Revenue growth YoY (%) | -64 |
Net loss growth YoY (%) | 48 |
Net margin (%) | -783 |
Income Statement (AUD) (Half-Yearly)
| Metric | H1 FY2017 (Dec 2016 half) | H1 FY2021 (Dec 2020 half) |
|---|---|---|
Revenue (AUD) | 1,990,000 | 81,000 |
Net loss (AUD) | -938,700 | -450,000 |
Key Financials (AUD) and Per-Share Data
| Metric | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
Accumulated losses at year end (AUD) | -104,726,230 | -106,192,017 | -107,620,001 |
Net tangible assets per share (AUD) | — | -0.00045 | -0.0005 |
Financial Analysis
| Metric | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Dividends paid (AUD) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD) | 0 | 0 | 0 | 0 | 0 |
Region Overview
| Region | Activity | Period | Evidence |
|---|---|---|---|
Australia | PeriCoach direct and clinician sales; TGA-registered; Queensland manufacturing plan | 2014–2023 | Company releases; Queensland Government |
United States | FDA-cleared; launched 23 Jun 2015; Current Technology, Inc. distribution; Denver sales lead | 2015–c.2018 | BioSpace |
United Kingdom / EU | CE mark; UK distribution agreements (2015–16) | 2015–c.2018 | Wholesale Investor |
China, Macau, Hong Kong, Taiwan | JV with Hebei Nacol Bio-Technology and Shijiazhuang Biosphere | 2021–2023 | BioWorld; Stockhead |
Middle East (ten nations) | Distribution of the infusion system and PeriCoach through Analytica Export ME | 2021–2023 | AuManufacturing; Owler log |
Region | FY2020 | FY2021 | FY2022 |
Total revenue (AUD) | — | — | 285,726 |
Valuation Snapshot
| Metric | Value | Source / date |
|---|---|---|
Last traded price (AUD) | 0.001 | Biotech Daily, 25 Jul 2023 |
Last reference market cap (AUD Mn) | 4.61 | MarketBeat |
Shares on issue (approx., M) | 4,610 | Implied by aggregator market cap at A$0.001 |
P/E | Not meaningful (losses) | — |
EV/Sales | Not computable (net debt not disclosed) | — |
Price/Sales (aggregator TTM) | 14.47 | iocharts |
P/B | Not meaningful (negative tangible equity) | — |
Share Price & Returns
| Period | Annualised return (%) |
|---|---|
3-year | -26.32 |
5-year | -30.12 |
10-year | -25.74 |
Share Price and Market Valuation
| Metric | 2017 | 2021 | 2023 |
|---|---|---|---|
Share price (AUD) | 0.005 | 0.002 | 0.001 |
Market cap (AUD Mn) | 13 | — | 4.61 |
Shares on issue (M) | 2,549 | — | 4,610 |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None (no broker coverage identified) |
Dividend history / policy | No dividends ever paid |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | Not publicly disclosed. Debt consisted mainly of director/related-party loans (about A$3.1M of chair-associated claims at the DOCA). |
Listed options | ALTOB, expired 18 June 2023 |
Analyst Conclusions
Management guidance. None. The company is delisted, its business has been sold, and the listed shell was slated for solvent winding-up.
Consensus growth expectations. None. There is no coverage.
Bull-case arguments (for the PeriCoach asset under private ownership)
-
The technology is validated. FDA (including OTC), CE and TGA clearances and multi-jurisdiction patents mean that Stratos acquired a regulatory-ready, IP-protected device for a very small consideration (A$290k deed fund).
-
The structural market need is real. About 1 in 3 women have pelvic-floor problems, and there is a roughly US$7B US pad market to substitute into. Femtech capital flows support the category.
-
Clean-slate economics. Stripped of listed-company costs and A$107M of historic losses, a lean private operator in Maryborough could run PeriCoach as a profitable niche business.
Bear-case arguments
-
A decade of commercial failure. Revenue never went above a few hundred thousand dollars a year from product sales, and it fell 64% in FY2022 even after the China and Middle East deals.
-
Competitive displacement. Better-funded consumer brands such as Elvie and Perifit now dominate attention in connected pelvic-floor training.
-
Successor status is uncertain. Stratos's Class I ARTG entry was cancelled within three months (April 2024), and no subsequent commercial activity has been verified.
Key catalysts and monitorables (next 12 months)
-
Completion records for the winding-up of Analytica Limited (ASIC registry status).
-
Any Stratos Medtech TGA, FDA or NMPA registrations or relaunch of PeriCoach.
-
The status of Queensland AQIAF grant repayment obligations, if milestones were missed.
-
Any activity from the China JV (Hebei Nacol) involving PeriCoach.
-
Clarification of the post-2023 ALT code usage reported by data aggregators.
Concluding analyst verdict
Analytica Limited no longer exists as an investable listed security, and for public-equity purposes the investment case is closed. Ordinary shareholders lost effectively all of their value. The shares last traded at 0.1 cents, and the operating business was sold under a DOCA that funded only A$290,000 for administrator costs and creditor claims. About A$3.1 million of those claims belonged to entities associated with the chairman. The outcome caps a 23-year listed history. By June 2022 that history had produced roughly A$107.6 million of accumulated losses, against annual revenue that peaked in the hundreds of thousands of dollars and fell to A$285,726 in the company's final full year.
The company's failure was not mainly technological. PeriCoach was a credible, well-regulated, patented product that reached market early, cleared the FDA's over-the-counter bar and attracted distinguished directors. The failure was commercial and financial. Analytica could never fund the consumer marketing that femtech adoption requires, never secured the multinational partner it publicly sought from 2015, and spent its final two listed years on a capital-intensive manufacturing pivot that depended on government grants and that the balance sheet could not support. Concentrated insider funding kept the company alive but also shaped its endgame: a sale to newly formed buyers in the chairman's home town, with control of the shell returning to the directors.
For analysts, the case is a useful reference for ASX micro-cap medtech. Regulatory approval is not commercial validation. Sub-cent capital raising compounds dilution without building scale. Related-party lenders ultimately decide how an insolvency is resolved. Any residual interest now lies only in monitoring whether Stratos Medtech can commercialise PeriCoach privately. Early signals, including the cancelled 2024 ARTG entry, are not encouraging. Verdict: Delisted, no equity value; monitor the successor asset only.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / notes | Source |
|---|---|---|---|
Dr Michael Monsour | Chairman | Chairman from at least 2014 to 2023. Lives in Maryborough. Largest shareholder (22% in 2017). His associated entities were owed about A$3.1M at the DOCA. | Biotech Daily 2017, 2023 |
Geoff Daly | CEO; earlier Operations Manager (2014) | CEO c.2015–2023. | Australian Manufacturing; Stockopedia |
Ross Mangelsdorf | Director; CFO (per aggregator) | Director from at least 2017; held 2.4% (2017) | Biotech Daily 2017; Datanyze |
Warren Brooks | Non-executive director | Board member as of 2017 | Biotech Daily 2017 |
Carl Stubbings | Non-executive director | Board member as of 2017 | Biotech Daily 2017 |
Dr Thomas Lönngren | Non-executive director | Board member as of 2017; former Executive Director of the European Medicines Agency (public record) | Biotech Daily 2017 |
Dr Peter Corr | Non-executive director | Board member as of 2017; 13% holder (2017); former senior Pfizer R&D executive (public record) | Biotech Daily 2017 |
Megan Henken | VP Global Sales & Marketing (Denver) | c. 2015 | BioSpace |
Major Shareholders
| Holder | Stake | As at |
|---|---|---|
Dr Michael Monsour (and associates) | 22% | 2,017 |
Dr Peter Corr | 13% | 2,017 |
Ross Mangelsdorf | 2.4% | 2,017 |
Institutional holders | Not publicly disclosed; likely negligible given micro-cap status | — |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Product | Ownership |
|---|---|---|---|
Connected pelvic-floor trainers | Chiaro Technology Ltd (UK) | Elvie Trainer | Private |
Connected pelvic-floor trainers | X6 Innovations (France) | Perifit | Private |
Connected pelvic-floor trainers | Minna Life (US) | kGoal | Private |
Pelvic-floor stimulation | InControl Medical (US) | InTone / Attain | Private |
Prescription pelvic-floor devices | Axena Health (formerly Renovia, US) | leva | Private |
Clinic-based pelvic-floor therapy | BTL Industries | Emsella chair | Private |
Clinical biofeedback / urodynamics | Laborie Medical Technologies | Pelvic-floor biofeedback systems | Private (PE-owned) |
Continence pads (substitute) | Essity (TENA), Kimberly-Clark (Poise) | Absorbent products | Listed large-caps |
IV infusion sets / burettes | B. Braun; Baxter; ICU Medical | Burette and infusion sets | Private / listed large-caps |
China pelvic rehabilitation | Domestic Chinese electro-stimulation and biofeedback makers | Postpartum rehabilitation devices | Various |
Competitor Detail
| Metric | Analytica (FY2022) |
|---|---|
Revenue | A$285,726 |
Revenue growth | -64% |
Net margin | About -783% |
Regulatory | TGA, CE, FDA (OTC) |
Recent Developments
The company stopped publishing disclosures in mid-2023, so an 18-month window from today has no company newsflow.
Discrepancy flag: * Market Index lists "Final/Estimated Distribution Announcement" notices dated 1 July 2024, 9 October 2024 and 1 July 2025 under the code ALT, labelled "Analytica Limited, Healthcare". These postdate Analytica's removal from the Official List. They are most likely a ticker-code reassignment or a data-provider mapping error, not Analytica disclosures. They are excluded from this analysis.



